Last reviewed · How we verify

Placebo BAI

Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3 active Small molecule

Placebo BAI is a Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc.. It is currently in Phase 3 development for Clinical trial control comparator (not a therapeutic indication). Also known as: breath-actuated inhaler.

Placebo BAI is an inert substance with no active pharmacological mechanism.

Placebo BAI is an inert substance with no active pharmacological mechanism. Used for Clinical trial control comparator (not a therapeutic indication).

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePlacebo BAI
Also known asbreath-actuated inhaler
SponsorTeva Branded Pharmaceutical Products R&D, Inc.
ModalitySmall molecule
PhasePhase 3

Mechanism of action

As a placebo, this agent contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo response—a psychobiological phenomenon where patient expectation and clinical context influence symptom perception and outcomes. Placebo BAI is used as a control comparator in clinical trials to distinguish true drug efficacy from placebo effects.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo BAI

What is Placebo BAI?

Placebo BAI is a Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc., indicated for Clinical trial control comparator (not a therapeutic indication).

How does Placebo BAI work?

Placebo BAI is an inert substance with no active pharmacological mechanism.

What is Placebo BAI used for?

Placebo BAI is indicated for Clinical trial control comparator (not a therapeutic indication).

Who makes Placebo BAI?

Placebo BAI is developed by Teva Branded Pharmaceutical Products R&D, Inc. (see full Teva Branded Pharmaceutical Products R&D, Inc. pipeline at /company/teva-branded-pharmaceutical-products-r-d-inc).

Is Placebo BAI also known as anything else?

Placebo BAI is also known as breath-actuated inhaler.

What development phase is Placebo BAI in?

Placebo BAI is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing